PER-117-10
Completed
未知
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline,0 sites0 target enrollmentJuly 4, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- GlaxoSmithKline,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female ≥ 18 years of age
- •Histologically or cytologically confirmed invasive breast cancer with distant metastasis(ses) (designated as Stage IV or metastatic breast cancer) Diagnosis with Stage IV or metastatic disease at either primary diagnosis or recurrence
- •Not received prior systemic or local treatment (e.g., chemotherapy, endocrine or radiotherapy) for Stage IV/metastatic breast cancer. Prior adjuvant and/or neo\-adjuvant therapy is permitted
- •Documentation of HER2 overexpression or gene amplification, in the invasive component of either a metastatic disease site or primary tumor, defined as: 3\+ by IHC and/or HER2/neu gene amplification by fluorescence, chromogenic or silver in situ hybridization \[FISH, CISH or SISH; \>6 HER2/neu gene copies per nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals) of ≥2\.0]
- •Documentation by the central laboratory of positive p95HER2 expression in the invasive component of either a metastatic disease site (preferred) or primary tumor
- •No history of CNS metastases (including leptomeningeal involvement) or stable CNS metastases (defined as asymptomatic and off steroids for ≥ 3 months)
- •Baseline Left Ventricular Ejection Fraction (LVEF) ≥50% measured by echocardiography (ECHO) or multi\-gated acquisition scan (MUGA)
- •Recovered or stabilized from all adverse events associated with prior anti\-cancer therapies, including radiotherapy, at the time of screening
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\-2
- •Have adequate marrow and organ function as defined as:
Exclusion Criteria
- •History of other malignancy. Exception: Subjects who have been disease\-free for 5 years or subjects with a history of completely resected non\-melanoma skin cancer (basal or squamous) are eligible
- •Concurrent anti\-cancer treatment or concurrent treatment with an investigational drug
- •Administration of an investigational drug within 30 days or 5 half\-lives, whichever is longer, preceding the first dose of study treatment
- •Prior treatment with anti\-HER2 therapy, except trastuzumab or lapatinib (time from last dose of trastuzumab or lapatinib to randomization must be ≥3 months)
- •Serious cardiac illness or medical condition including but not confined to: Uncontrolled arrhythmias, Uncontrolled or symptomatic angina, History of congestive heart failure (CHF), Documented myocardial infarction \<6 months from study entry
- •Current active hepatic or biliary disease (with exception of Gilbert´s syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •Concurrent disease or condition, or any pre\-existing medical disorder that in the opinion of the investigator may interfere with the subject´s safety, obtaining informed consent or compliance to the study procedures
- •Pregnant or lactating female
- •Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels (consult with GSK Medical Monitor if uncertain about eligibility)
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study drugs or their excipients that, in the opinion of the investigator contra\-indicates participation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast Cancer - n/aEUCTR2010-019390-15-IEGlaxoSmithKline Research & Development Ltd300
Active, not recruiting
Not Applicable
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast Cancer - n/aBreast Cancer (HER2-positive and p95HER2-positive metastaticbreast cancer)MedDRA version: 12.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2010-019390-15-PLGlaxoSmithKline Research & Development Ltd300
Completed
Not Applicable
Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. GLICO-0801-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-059-09Grupo Latinoamericano de Investigaciones Clinicas en Oncologica (GLICO),
Active, not recruiting
Not Applicable
An open-label, Phase II randomised trial of Lapatinib (TYKERB?) + Pemetrexed (Alimta) versus Pemetrexed in the Second Line Treatment of advanced or metastatic Non Small Cell Lung Cancer - Lapatinib + Pemetrexed vs Pemetrexed in NSCLCEUCTR2007-002472-34-ITGlaxoSmithkine Research and Development Ltd220
Active, not recruiting
Phase 1
A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-oncology Therapy after Prior Treatment with Tyrosine Kinase InhibitorsEUCTR2018-003151-38-PLBristol-Myers Squibb International Corporation250